Skip to main content

Advertisement

SpringerLink
Log in

Sensory Neuronopathies

  • Nerve and Muscle (L H Weimer, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The sensory neuronopathies are sensory-predominant polyneuropathies that result from damage to the dorsal root and trigeminal sensory ganglia. This review explores the various causes of acquired sensory neuronopathies, the approach to diagnosis, and treatment.

Recent Findings

Diagnostic criteria have recently been published and validated to allow differentiation of sensory neuronopathies from other polyneuropathies. On the basis of serial electrodiagnostic studies, the treatment window for the acquired sensory neuronopathies has been identified as approximately 8 months. If treatment is initiated within 2 months of symptom onset, there is a better opportunity for improvement of the patient's condition.

Summary

Even though sensory neuronopathies are rare, significant progress has been made regarding characterization of their clinical, electrophysiologic, and imaging features. This does not hold true, however, for treatment. There have been no randomized controlled clinical trials to guide management of these diseases, and a standard treatment approach remains undetermined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72:78–90.

    Article  CAS  PubMed  Google Scholar 

  2. Lax NZ, Whittaker RG, Hepplewhite PD, Reeve AK, Blakely EL, Jaros E, et al. Sensory neuronopathy in patients harbouring recessive polymerase γ mutations. Brain. 2012;135:62–71.

    Article  PubMed  Google Scholar 

  3. Szmulewicz DJ, McLean CA, Rodriguez ML, Chancellor AM, Mossman S, Lamont D, et al. Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology. 2014;82:1410–5.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bejaoui K, Wu C, Scheffler MD, Haan G, Ashby P, Wu L, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet. 2001;27:261–2.

    Article  CAS  PubMed  Google Scholar 

  5. Vucic S, Tian D, Chong PST, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006;129:3384–90.

    Article  CAS  PubMed  Google Scholar 

  6. Colli BO, Carlotti CG, Assirati JA. Lopes L da S, Marques W, Chimelli L, et al. Dorsal root ganglionectomy for the diagnosis of sensory neuropathies. Surgical technique and results. Surg Neurol. 2008;69:266–73. discussion 273

    Article  PubMed  Google Scholar 

  7. Oh SJ, Gürtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116:28–34.

    Article  PubMed  Google Scholar 

  8. Antoine JC, Honnorat J, Camdessanché JP, Magistris M, Absi L, Mosnier JF, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001;49:214–21.

    Article  CAS  PubMed  Google Scholar 

  9. Ogawa M, Nishie M, Kurahashi K, Kaimori M, Wakabayashi K. Anti-Hu associated paraneoplastic sensory neuronopathy with upper motor neurone involvement. J Neurol Neurosurg Psychiatry. 2004;75:1051–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249:745–53.

    Article  PubMed  Google Scholar 

  11. Wabbels BK, Elflein H, Lorenz B, Kolling G. Bilateral tonic pupils with evidence of anti-Hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica. 218:141–3.

  12. Wymenga ANM, Slebos DJ, van der Naalt J, van Putten JWG, Peters FTM. Buikklachten en neurologische symptomen als vroege manifestatie van longkanker: een uiting van het anti-Hu-syndroom. Ned Tijdschr Geneeskd. 2003;147:616–9.

  13. Briellmann RS, Sturzenegger M, Gerber HA, Schaffner T, Hess CW. Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Eur Neurol. 1996;36:369–73.

    Article  CAS  PubMed  Google Scholar 

  14. Wildhaber B, Niggli F, Stallmach T, Willi U, Stauffer UG, Sacher P. Intestinal pseudoobstruction as a paraneoplastic syndrome in ganglioneuroblastoma. Eur J Pediatr Surg. 2002;12:429–31.

    Article  CAS  PubMed  Google Scholar 

  15. Camdessanché J-P, Antoine J-C, Honnorat J, Vial C, Petiot P, Convers P, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125:166–75.

    Article  PubMed  Google Scholar 

  16. Taieb G, Renard D, Deverdal M, Honnorat J, Labauge P, Castelnovo G. Pure monomelic sensory neuronopathy associated with anti-yo antibodies. Muscle Nerve. 2012;45:297–8.

    Article  PubMed  Google Scholar 

  17. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56:172–7.

    Article  CAS  PubMed  Google Scholar 

  18. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.

    Article  CAS  PubMed  Google Scholar 

  19. Côté-Mantha E, Savard M. Paraneoplastic anti-HU syndrome associated with uterine tumor. Can J Neurol Sci. 2012;39:254–5.

    Article  PubMed  Google Scholar 

  20. Fournier CN, Kalra A, Lachance DH, Zarwan C, Srinivasan J. ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor. Muscle Nerve. 2013;47:776–7.

    Article  PubMed  Google Scholar 

  21. Sano T, Tanaka K, Ito N. Anti-Hu-antibody-associated paraneoplastic neurological syndrome accompanying testicular cancer. Int J Urol. 2010;17:99.

    Article  PubMed  Google Scholar 

  22. Lukacs S, Szabo N, Woodhams S. Rare association of anti-Hu antibody positive paraneoplastic neurological syndrome and transitional cell bladder carcinoma. Case Rep Urol. 2012;2012:724940.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Cowley A, Pascoe S. Paraneoplastic subacute sensory neuronopathy in association with adenocarcinoma of the prostate. BMJ Case Rep. 2011; doi:10.1136/bcr.04.2011.4077.

  24. Matsui T, Hori Y, Nagano H, Eguchi H, Marubashi S, Wada H, et al. Poorly differentiated hepatocellular carcinoma accompanied by anti-Hu antibody-positive paraneoplastic peripheral neuropathy. Pathol Int. 2015;65:388–92.

  25. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51:1146–50.

    Article  CAS  PubMed  Google Scholar 

  26. Tomita M, Koike H, Kawagashira Y, Iijima M, Adachi H, Taguchi J, et al. Clinicopathological features of neuropathy associated with lymphoma. Brain. 2013;136:2563–78.

    Article  PubMed  Google Scholar 

  27. Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2:e27384.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol. 1995;38:102–10.

    Article  CAS  PubMed  Google Scholar 

  29. Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Cañete A, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer. 1995;75:99–109.

    Article  CAS  PubMed  Google Scholar 

  30. Kuntzer T, Antoine J-C, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30:255–68.

    Article  PubMed  Google Scholar 

  31. •• Antoine J-C, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, et al. Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies. J Neurol Sci. 2016;361:187–91. The authors retrospectively studied the electrophysiological study findings of 86 patients with inflammatory sensory neuronopathy. They used the sensory nerve action potentials as a surrogate marker of neuronal degeneration. The sensory responses declined rapidly in the first 2 months, the decline slowed down after 7 months, and stabilized after 10 months. They concluded that there is a brief therapeutic window of 8 months. Abatement of the disease is possible if treatment is initiated in the first 2 months.

    Article  PubMed  Google Scholar 

  32. Antoine J-C, Camdessanché J-P. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol. 2013;15:210–23.

    Article  PubMed  Google Scholar 

  33. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve. 1997;20:1576–82.

    Article  CAS  PubMed  Google Scholar 

  34. Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol. 2013;14:528–38.

    Article  PubMed  Google Scholar 

  35. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60:388–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Graus F, Vega F, Delattre JY, Bonaventura I, Reñé R, Arbaiza D, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536–40.

    Article  CAS  PubMed  Google Scholar 

  37. Shams’ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, van’t Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253:16–20.

    Article  PubMed  CAS  Google Scholar 

  38. de Jongste AH, van Gelder T, Bromberg JE, de Graaf MT, Gratama JW, Schreurs MW, et al. A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro Oncol. 2015;17:145–50.

    Article  PubMed  Google Scholar 

  39. Malinow K, Yannakakis GD, Glusman SM, Edlow DW, Griffin J, Pestronk A, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren’s syndrome. Ann Neurol. 1986;20:535–7.

    Article  CAS  PubMed  Google Scholar 

  40. Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27–33.

    Article  CAS  PubMed  Google Scholar 

  41. • Pereira PR, Viala K, Maisonobe T, Haroche J, Mathian A, Hié M, et al. Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine (Baltimore). 2016;95:e3632. This is a retrospective study of 13 patients with Sjögren's syndrome-associated sensory neuronopathy. Patients presented most often with ataxia and areflexia. They were treated with a number of therapies, including corticosteroids, mycophenolate mofetil, hydroxychloroquine, and intravenous immune globulin. The authors concluded that Sjögren's syndrome-associated sensory neuronopathy is heterogeneous, insidious, chronic, and debilitating despite treatment. The patients treated with immunosuppressive drugs such as mycophenolate mofetil and corticosteroids did well compared with those treated with intravenous immune globulin.

    Article  Google Scholar 

  42. Brito-Zerón P, Akasbi M, Bosch X, Bové A, Pérez-De-Lis M, Diaz-Lagares C, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2013;31:103–10.

    PubMed  Google Scholar 

  43. Carvajal Alegria G, Guellec D, Devauchelle-Pensec V, Saraux A. Is there specific neurological disorders of primary Sjögren’s syndrome? Joint Bone Spine. 2015;82:86–9.

    Article  PubMed  Google Scholar 

  44. Fauchais A-L, Magy L, Vidal E. Central and peripheral neurological complications of primary Sjögren’s syndrome. Presse Med. 2012;41:e485–93.

    Article  PubMed  Google Scholar 

  45. Griffin JW, Cornblath DR, Alexander E, Campbell J, Low PA, Bird S, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol. 1990;27:304–15.

    Article  CAS  PubMed  Google Scholar 

  46. Mori K, Iijima M, Koike H, Hattori N, Tanaka F, Watanabe H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128:2518–34.

    Article  PubMed  Google Scholar 

  47. Damasceno A, França MC, Cury H, Nucci A. Autonomic dysfunction in non-paraneoplastic sensory neuronopathy: beyond sensory abnormalities. J Neurol. 2011;258:231–7.

    Article  PubMed  Google Scholar 

  48. Mellgren SI, Göransson LG, Omdal R. Primary Sjögren’s syndrome associated neuropathy. Can J Neurol Sci. 2007;34:280–7.

    Article  PubMed  Google Scholar 

  49. Chen WH, Yeh JH, Chiu HC. Plasmapheresis in the treatment of ataxic sensory neuropathy associated with Sjögren’s syndrome. Eur Neurol. 2001;45:270–4.

    Article  PubMed  Google Scholar 

  50. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35:66–9.

    Article  CAS  PubMed  Google Scholar 

  51. Santosa A, Lim AYN, Vasoo S, Lau TC, Teng GG. Neurosjögren: early therapy is associated with successful outcomes. J Clin Rheumatol. 2012;18:389–92.

    Article  PubMed  Google Scholar 

  52. Martinez ARM, Nunes MB, Nucci A, França MC. Sensory neuronopathy and autoimmune diseases. Autoimmune Dis. 2012;2012:873587.

    PubMed  PubMed Central  Google Scholar 

  53. Rist S, Sellam J, Hachulla E, Sordet C, Puéchal X, Hatron P, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63:1339–44.

    Article  Google Scholar 

  54. Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjögren’s syndrome. IV immunoglobulin. Neurology. 2003;60:503–5.

    CAS  PubMed  Google Scholar 

  55. Caroyer J-M, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren’s syndrome. Neurology. 2002;59:1113–4.

    Article  PubMed  Google Scholar 

  56. Goodman BP. Immunoresponsive autonomic neuropathy in Sjögren syndrome—case series and literature review. Am J Ther. 2017; doi:10.1097/MJT.0000000000000583.

  57. Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grünewald RA, Davies-Jones AGB. Sensory ganglionopathy due to gluten sensitivity. Neurology. 2010;75:1003–8.

    Article  CAS  PubMed  Google Scholar 

  58. Marsh MN. The natural history of gluten sensitivity: defining, refining and re-defining. QJM. 1995;88:9–13.

    CAS  PubMed  Google Scholar 

  59. Hadjivassiliou M, Williamson CA, Woodroofe N. The immunology of gluten sensitivity: beyond the gut. Trends Immunol. 2004;25:578–82.

    Article  CAS  PubMed  Google Scholar 

  60. Reda H, Chin RL. Peripheral neuropathies of rheumatologic disease and gluten-related disorders. Semin Neurol. 2014;34:413–24.

    Article  PubMed  Google Scholar 

  61. Brannagan TH, Hays AP, Chin SS, Sander HW, Chin RL, Magda P, et al. Small-fiber neuropathy/neuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol. 2005;62:1574–8.

    Article  PubMed  Google Scholar 

  62. McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J. The neurologic significance of celiac disease biomarkers. Neurology. 2014;83:1789–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Volta U, De Giorgio R. Gluten sensitivity: an emerging issue behind neurological impairment? Lancet Neurol. 2010;9:233–5.

    Article  PubMed  Google Scholar 

  64. Merchut MP, Adams EM, Morrissey M. Sensory neuronopathy in autoimmune chronic active hepatitis. Neurology. 1993;43:2410–1.

    Article  CAS  PubMed  Google Scholar 

  65. Magy L, Bassez G, Chassande B, Poynard T, Léger JM. Neuronopathie sensitive associee a une hepatite chronique auto-immune. Rev Neurol (Paris). 1997;153:70–2.

  66. Liedholm LJ, Månsson A, Holmgren H. Subakuta sensoriska neuropatier. Nord Med. 1994;109:296–7. 309

  67. Navinan MR, Piranavan P, Akram AUA, Yudhishdran J, Kandeepan T, Kulatunga A. Sensory neuronopathy complicating systemic lupus erythematosus: a case report. J Med Case Rep. 2014;8:141.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Wang J-C, Lin Y-C, Yang T-F, Lin H-Y. Ataxic sensory neuronopathy in a patient with systemic lupus erythematosus. Lupus. 2012;21:905–9.

    Article  PubMed  Google Scholar 

  69. Alix JJP, Hadjivassiliou M, Ali R, Slater D, Messenger AG, Rao DG. Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy. Muscle Nerve. 2015;51:296–301.

    Article  CAS  PubMed  Google Scholar 

  70. •• Antoine J-C, Boutahar N, Lassablière F, Reynaud E, Ferraud K, Rogemond V, et al. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry. 2015;86:1347–55. The authors identified anti-fibroblast growth factor receptor 3 antibodies in 17 patients, 16 of whom had a sensory neuropathy. The authors concluded that these antibodies may be seen in patients with an underlying autoimmune disorder affecting the dorsal root and trigeminal nerve ganglia as 87% of patients had a non-length-dependent neuropathy consistent with sensory neuronopathy.

    Article  PubMed  Google Scholar 

  71. Kulkantrakorn K. Pyridoxine-induced sensory ataxic neuronopathy and neuropathy: revisited. Neurol Sci. 2014;35:1827–30.

    Article  PubMed  Google Scholar 

  72. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309:445–8.

    Article  CAS  PubMed  Google Scholar 

  73. Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology. 1989;39:1077–83.

    Article  CAS  PubMed  Google Scholar 

  74. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985;35:1466–8.

    Article  CAS  PubMed  Google Scholar 

  75. Perry TA, Weerasuriya A, Mouton PR, Holloway HW, Greig NH. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol. 2004;190:133–44.

    Article  CAS  PubMed  Google Scholar 

  76. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13:27–46.

    Article  CAS  PubMed  Google Scholar 

  77. Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.

    Article  CAS  PubMed  Google Scholar 

  78. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116:2322–31.

    CAS  PubMed  Google Scholar 

  79. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130:1076–88.

    Article  CAS  PubMed  Google Scholar 

  80. Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol. Dis. 2011;41:661–8.

    Article  CAS  PubMed  Google Scholar 

  82. Maj MA, Ma J, Krukowski KN, Kavelaars A, Heijnen CJ. Inhibition of mitochondrial p53 accumulation by PFT-μ prevents cisplatin-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:108.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Novak P, Pimentel DA, Sundar B, Moonis M, Qin L, Novak V. Association of statins with sensory and autonomic ganglionopathy. Front Aging Neurosci. 2015;7:191.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Rance NE, McArthur JC, Cornblath DR, Landstrom DL, Griffin JW, Price DL. Gracile tract degeneration in patients with sensory neuropathy and AIDS. Neurology. 1988;38:265–71.

    Article  CAS  PubMed  Google Scholar 

  85. Scaravilli F, Sinclair E, Arango JC, Manji H, Lucas S, Harrison MJ. The pathology of the posterior root ganglia in AIDS and its relationship to the pallor of the gracile tract. Acta Neuropathol. 1992;84:163–70.

    Article  CAS  PubMed  Google Scholar 

  86. Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol. 2005;4:349–61.

    Article  CAS  PubMed  Google Scholar 

  87. Rubin DI, Daube JR. Subacute sensory neuropathy associated with Epstein-Barr virus. Muscle Nerve. 1999;22:1607–10.

    Article  CAS  PubMed  Google Scholar 

  88. Ramos F, Monforte C, Luengo Neuronopatia aguda sensitiva asociada a infeccion por virus varicela-zoster. Rev. Neurol. 1999;28:1067–9.

  89. Shimazaki R, Ueyama H, Mori T, Mori M, Fujimoto S, Kumamoto T, et al. Chronic sensory neuronopathy associated with human T-cell lymphotropic virus type I infection. J Neurol Sci. 2002;194:55–8.

    Article  CAS  PubMed  Google Scholar 

  90. Mansukhani KA, Khadilkar SV. Consider leprosy as an etiology of sensory neuronopathy. Muscle Nerve. 2017;55:928.

    Article  PubMed  Google Scholar 

  91. Chiu C-C, Yang C-Y, Yang T-F, Lin K-P, Huang S-H, Wang J-C. Acute sensory neuronopathy following enterovirus infection in a 3-year-old girl. Neuropediatrics. 2017;48:190–3.

    Article  PubMed  Google Scholar 

  92. Dalakas MC. Chronic idiopathic ataxic neuropathy. Ann Neurol. 1986;19:545–54.

    Article  CAS  PubMed  Google Scholar 

  93. van Dijk GW, Wokke JH, Notermans NC, van den Berg LH, Bär PR. Indications for an immune-mediated etiology of idiopathic sensory neuronopathy. J Neuroimmunol. 1997;74:165–72.

    Article  PubMed  Google Scholar 

  94. Camdessanché J-P, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132:1723–33.

    Article  PubMed  PubMed Central  Google Scholar 

  95. • Antoine J-C, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, et al. Testing the validity of a set of diagnostic criteria for sensory neuronopathies: a francophone collaborative study. J Neurol. 2014;261:2093–100. The sensory neuronopathy criteria, published in 2009, were validated in 210 patients in a multicenter French study.

    Article  PubMed  Google Scholar 

  96. Lauria G, Pareyson D, Sghirlanzoni A. Neurophysiological diagnosis of acquired sensory ganglionopathies. Eur Neurol. 2003;50:146–52.

    Article  PubMed  Google Scholar 

  97. Sterman AB, Schaumburg HH, Asbury AK. The acute sensory neuronopathy syndrome: a distinct clinical entity. Ann Neurol. 1980;7:354–8.

    Article  CAS  PubMed  Google Scholar 

  98. Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, Karnes JL. The syndrome of acute sensory neuropathy: clinical features and electrophysiologic and pathologic changes. Neurology. 1990;40:584–91.

    Article  CAS  PubMed  Google Scholar 

  99. Rothwell JC, Traub MM, Day BL, Obeso JA, Thomas PK, Marsden CD. Manual motor performance in a deafferented man. Brain. 1982;105(Pt 3):515–42.

    Article  PubMed  Google Scholar 

  100. Molinuevo JL, Graus F, Serrano C, Reñe R, Guerrero A, Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol. 1998;44:976–80.

    Article  CAS  PubMed  Google Scholar 

  101. Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci. 1992;19:346–51.

    CAS  PubMed  Google Scholar 

  102. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(Pt 7):1481–94.

    Article  PubMed  Google Scholar 

  103. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Roentgenol. 1998;170:1513–7.

    Article  CAS  PubMed  Google Scholar 

  104. Bannas P, Weber C, Derlin T, Lambert J, Leypoldt F, Adam G, et al. 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. Eur Radiol. 2010;20:923–30.

    Article  PubMed  Google Scholar 

  105. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19–e3.

    Article  CAS  PubMed  Google Scholar 

  106. Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol. 2000;47:104–9.

    Article  CAS  PubMed  Google Scholar 

  107. Bao Y-F, Tang W-J, Zhu D-Q, Li Y-X, Zee C-S, Chen X-J, et al. Sensory neuronopathy involves the spinal cord and brachial plexus: a quantitative study employing multiple-echo data image combination (MEDIC) and turbo inversion recovery magnitude (TIRM). Neuroradiology. 2013;55:41–8.

    Article  PubMed  Google Scholar 

  108. Casseb RF, de Paiva JLR, Branco LMT, Martinez ARM, Reis F, de Lima-Junior JC, et al. Spinal cord diffusion tensor imaging in patients with sensory neuronopathy. Neuroradiology. 2016;58:1103–8.

    Article  PubMed  Google Scholar 

  109. Gorson KC, Ropper AH. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications. Muscle Nerve. 2003;28:553–60.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Virginia, P.O. Box 800394, Charlottesville, VA, 22908, USA

    Allison Crowell & Kelly G. Gwathmey

Authors
  1. Allison Crowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kelly G. Gwathmey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly G. Gwathmey.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Nerve and Muscle

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crowell, A., Gwathmey, K.G. Sensory Neuronopathies. Curr Neurol Neurosci Rep 17, 79 (2017). https://doi.org/10.1007/s11910-017-0784-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-017-0784-4

Keywords

Search

Navigation